Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Voltammetric Methods Used in the Determination of Nucleoside Reverse Transcriptase Inhibitors

Author(s): Fatma Ağın* and İnci Selin Doğan

Volume 17, Issue 3, 2021

Published on: 19 May, 2020

Page: [409 - 420] Pages: 12

DOI: 10.2174/1573412916999200519141257

Price: $65

Abstract

Background: The Human Immunodeficiency Virus (HIV) has now been established as the causative agent of the Acquired Immunodeficiency Syndrome (AIDS) and exactly 25 antiretroviral drugs have been formally approved for clinical use in the treatment of AIDS. The life quality and duration of HIV-positive patients have increased with the usage of antiretroviral drugs in the treatment of AIDS. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are one of the subgroups of antiretroviral.

Objective: The quantification of drugs is important, as they make positive contributions to dose adjustments in practice. Voltammetric methods are very powerful analytical methods used in the pharmaceutical industry because of the determination of therapeutic agents and/or their metabolites in clinical samples at extremely low concentrations (10-50 ng/ml).

Methods: This review mainly includes the pharmacological properties and recent determination studies by voltammetric methods from pharmaceutical dosage forms and biological samples of eight NRTIs group antiretroviral drugs (zidovudine, abacavir, adefovir, entecavir, zalcitabine, didanosine, emtricitabine, lamivudine) that are used in the clinic and show electroactive properties, were performed.

Conclusion: Due to the variety of working electrodes in voltammetric methods, it is possible to choose the electrode that best responds. In this way, the analysis of NRTIs was possible at lower concentrations in pharmaceuticals and biological samples with voltammetric methods in these studies without the necessity for the sample pre-treatment or time-consuming extraction steps. The voltammetric methods provide good stability, repeatability, reproducibility and high recovery for the analysis of the analyte. They could be used for the pharmacokinetic studies as well as for quality control laboratory studies.

Keywords: Anti-HIV, analysis, antiretroviral determination, nucleoside reverse transcriptase inhibitors, voltammetric methods, virus.

« Previous Next »
Graphical Abstract

[1]
Woster, P.M. Antiviral Agents and Protease Inhibitors.Foye’s Principles of Medicinal Chemistry; Lemke, T.L.; Zito, S.W; Roche, V.F.Eds Lippincott Williams &Wilkins: New York, 2013, pp. 1267-1306.
[2]
Akgün, H.; Balkan, A.; Çalış, Ü.; Dalkara, S.; Erol, D.; Erdoğan, H.; Ertan, M.; Kelekçi, N.; Özkanlı, F.; Palaska, E.; Saraç, S.; Şafak, C.; Tozkoparan, B. Farmasötik Kimya, 6th ed; Hacettepe Üniversitesi Yayınları: Ankara, 2013.
[3]
Baron, S. Medical Microbiology, 3rd ed; Churchill Livingstone: New York, 1991, pp. 555-652.
[4]
Brooks, G.F.; Butel, J.S.; Morse, S.A. Jawettz, Melnick and Adelberg’s Medical Microbiology, 23rd ed; McGraw-Hill Companies: New York, 2004.
[5]
Gallo, R.C. History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene, 2005, 24(39), 5926-5930.
[http://dx.doi.org/10.1038/sj.onc.1208980] [PMID: 16155599]
[6]
Sierra, S.; Kupfer, B.; Kaiser, R. Basics of the virology of HIV-1 and its replication. J. Clin. Virol., 2005, 34(4), 233-244.
[http://dx.doi.org/10.1016/j.jcv.2005.09.004] [PMID: 16198625]
[7]
Gallo, R.C.; Montagnier, L. The discovery of HIV as the cause of AIDS. N. Engl. J. Med., 2003, 349(24), 2283-2285.
[http://dx.doi.org/10.1056/NEJMp038194] [PMID: 14668451]
[8]
HIV/AIDS. https://www.who.int/news-room/fact-sheets/detail/hiv-aids [Accessed February 06, 2020]
[9]
Ataman-Hatipoğlu, Ç.; Deveci, A.; Eren-Gök, Ş.; Kocagül-Çelikbaş, A.; Sayın-Kutlu, S.; Taşdelen-Fışgın, N. HIV Bilgilendirme Kitabı. Türkiye Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği; KLİMİK, 2016, pp. 1-27.
[10]
Taşdelen-Fışgın, N.; Tanyel, E.; Sarıkaya-Genç, H.; Tülek, N. HIV/AIDS Olgularının Değerlendirilmesi. Klimik Derg., 2009, 22(1), 18-20.
[11]
Bayraktar, B. HIV-General Features of the Virus. Turkiye Klinikleri J. Inf. Dis.-. Special Topics, 2016, 9(1), 1-5.
[12]
https://aidsinfo.nih.gov/understanding-hiv-aids/glossary/3/acquired-immunodeficiency-syndrome [Accessed February 07, 2020];
[13]
Irmak, H.; Yardım, N.; Keklik, K.; Temel, F. Türkiye HIV/AIDS kontrol programı 2019-2024; T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu: Ankara, 2019.
[14]
Özyurt, S. Human Endogenous Retroviruses and Psoriasis. Turkiye Klinikleri J. Dermatol., 2009, 19(2), 99-103. [Review
[15]
Urnovitz, H.B.; Murphy, W.H. Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin. Microbiol. Rev., 1996, 9(1), 72-99.
[http://dx.doi.org/10.1128/CMR.9.1.72] [PMID: 8665478]
[16]
Temin, H.M. The DNA provirus hypothesis. Science, 1976, 192(4244), 1075-1080.
[http://dx.doi.org/10.1126/science.58444] [PMID: 58444]
[17]
Weller, I.V.; Williams, I.G. ABC of AIDS. Antiretroviral drugs. BMJ, 2001, 322(7299), 1410-1412.
[http://dx.doi.org/10.1136/bmj.322.7299.1410] [PMID: 11397751]
[18]
Yoder, K.; Carter, A. About Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 2019.https://www.healthline.com/health/hiv-aids/nucleoside-nucleotide-reverse-transcriptase-inhibitors [Accessed February 07, 2020];
[19]
Waller, D.G.; Sampson, A.P. 51-Chemotherapy of infections, 5th ed; Medical Pharmacology and Therapeutics, 2018, pp. 581-629.
[20]
Buzgan, T.; Torunoğlu, M.A.; Gökengin, D. HIV infeksiyonlarının taranması ve tanısı. HIV/AIDS Tanı Tedavi Rehberi; T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu: Ankara, 2013, pp. 17-29.
[21]
Shen, L.; Peterson, S.; Sedaghat, A.R.; McMahon, M.A.; Callender, M.; Zhang, H.; Zhou, Y.; Pitt, E.; Anderson, K.S.; Acosta, E.P.; Siliciano, R.F. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med., 2008, 14(7), 762-766.
[http://dx.doi.org/10.1038/nm1777] [PMID: 18552857]
[22]
Department of Health and Human Services. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0 [Accessed February 05, 2020];
[23]
Moore, R.D.; Chaisson, R.E. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS, 1999, 13(14), 1933-1942.
[http://dx.doi.org/10.1097/00002030-199910010-00017] [PMID: 10513653]
[24]
Cohen, M.S.; Chen, Y.Q.; McCauley, M.; Gamble, T.; Hosseinipour, M.C.; Kumarasamy, N.; Hakim, J.G.; Kumwenda, J.; Grinsztejn, B.; Pilotto, J.H.S.; Godbole, S.V.; Chariyalertsak, S.; Santos, B.R.; Mayer, K.H.; Hoffman, I.F.; Eshleman, S.H.; Piwowar-Manning, E.; Cottle, L.; Zhang, X.C.; Makhema, J.; Mills, L.A.; Panchia, R.; Faesen, S.; Eron, J.; Gallant, J.; Havlir, D.; Swindells, S.; Elharrar, V.; Burns, D.; Taha, T.E.; Nielsen-Saines, K.; Celentano, D.D.; Essex, M.; Hudelson, S.E.; Redd, A.D.; Fleming, T.R. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N. Engl. J. Med., 2016, 375(9), 830-839.
[http://dx.doi.org/10.1056/NEJMoa1600693] [PMID: 27424812]
[25]
https://aidsinfo.nih.gov/understanding-hiv-aids/glossary/902/nucleoside-reverse-transcriptase-inhibitor [Accessed February 07, 2020];
[26]
Medically reviewed by Thomas Dean Chiampas, PharmD, BCPS, AAHIVP on November 27, 2019-Written by Kimberly Holland.. 2019.https://www.healthline.com/health/hiv-aids/evolution-of-hiv-treatments#types-of-antiretroviral-drugs [Accessed February 07, 2020];
[27]
Cavaletti, G. Toxic and Drug-Induced Neuropathies. Neurobiol. Dis., 2007, 871-883.
[28]
Bernardino, J.I.; Arrıbas, J.R. Antiviral Therapy, 4th ed; Infectious Diseases, 2017, Vol. 2, pp. 918-926.
[29]
El-Sadr, W.M.; Lundgren, J.; Neaton, J.D.; Gordin, F.; Abrams, D.; Arduino, R.C.; Babiker, A.; Burman, W.; Clumeck, N.; Cohen, C.J.; Cohn, D.; Cooper, D.; Darbyshire, J.; Emery, S.; Fätkenheuer, G.; Gazzard, B.; Grund, B.; Hoy, J.; Klingman, K.; Losso, M.; Markowitz, N.; Neuhaus, J.; Phillips, A.; Rappoport, C. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med., 2006, 355(22), 2283-2296.
[http://dx.doi.org/10.1056/NEJMoa062360] [PMID: 17135583]
[30]
Lundgren, J.D.; Babiker, A.G.; Gordin, F.; Emery, S.; Grund, B.; Sharma, S.; Avihingsanon, A.; Cooper, D.A.; Fätkenheuer, G.; Llibre, J.M.; Molina, J.M.; Munderi, P.; Schechter, M.; Wood, R.; Klingman, K.L.; Collins, S.; Lane, H.C.; Phillips, A.N.; Neaton, J.D. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N. Engl. J. Med., 2015, 373(9), 795-807.
[http://dx.doi.org/10.1056/NEJMoa1506816] [PMID: 26192873]
[31]
Riddler, S.A.; Haubrich, R.; DiRienzo, A.G.; Peeples, L.; Powderly, W.G.; Klingman, K.L.; Garren, K.W.; George, T.; Rooney, J.F.; Brizz, B.; Lalloo, U.G.; Murphy, R.L.; Swindells, S.; Havlir, D.; Mellors, J.W. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med., 2008, 358(20), 2095-2106.
[http://dx.doi.org/10.1056/NEJMoa074609] [PMID: 18480202]
[32]
Mitsuya, H. Anti-HIV Nucleosides: Past, Present and Future; Chapman and Hall: New York, 1997.
[33]
MacDonald, L.; Kazanjian, P. Antiretroviral therapy in HIV-infection: an update. Formulary, 1996, 31, 780-804.
[34]
Beach, J.W. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin. Ther., 1998, 20(1), 2-25.
[http://dx.doi.org/10.1016/S0149-2918(98)80031-3] [PMID: 9522101]
[35]
Neuzil, K.M. Pharmacologic therapy for human immunodeficiency virus infection: a review. Am. J. Med. Sci., 1994, 307(5), 368-373.
[http://dx.doi.org/10.1097/00000441-199405000-00011] [PMID: 7513499]
[36]
Hoth, D.F., Jr; Myers, M.W.; Stein, D.S. Current status of HIV therapy: I. Antiretroviral agents. Hosp. Pract. (Off. Ed.), 1992, 27(9), 145-156.
[http://dx.doi.org/10.1080/21548331.1992.11705488] [PMID: 1381716]
[37]
Elion, R.A.; Witt, M.D. Nucleoside and Nucleotide Reverse Transcritase Inhibitors in the Treatment of HIV: Focus on Efficacy; Medscape CME/CE, 2003.
[38]
Usach, I.; Melis, V.; Peris, J.E. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J. of the Inter. AIDS Soc., 2013, 16(1), 18567.
[http://dx.doi.org/10.7448/IAS.16.1.18567]
[39]
Piliero, P.J. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr., 2004, 37(Suppl. 1), S2-S12.
[http://dx.doi.org/10.1097/01.qai.0000137001.40505.56] [PMID: 15319664]
[40]
De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents, 2009, 33(4), 307-320.
[http://dx.doi.org/10.1016/j.ijantimicag.2008.10.010] [PMID: 19108994]
[41]
Cihlar, T.; Ray, A.S. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res., 2010, 85(1), 39-58.
[http://dx.doi.org/10.1016/j.antiviral.2009.09.014] [PMID: 19887088]
[42]
Arion, D.; Kaushik, N.; McCormick, S.; Borkow, G.; Parniak, M.A. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry, 1998, 37(45), 15908-15917.
[http://dx.doi.org/10.1021/bi981200e] [PMID: 9843396]
[43]
Quan, Y.; Rong, L.; Liang, C.; Wainberg, M.A. Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1. J. Virol., 1999, 73(8), 6700-6707.
[http://dx.doi.org/10.1128/JVI.73.8.6700-6707.1999] [PMID: 10400767]
[44]
Pruvost, A.; Negredo, E.; Benech, H.; Theodoro, F.; Puig, J.; Grau, E.; García, E.; Moltó, J.; Grassi, J.; Clotet, B. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother., 2005, 49(5), 1907-1914.
[http://dx.doi.org/10.1128/AAC.49.5.1907-1914.2005] [PMID: 15855513]
[45]
Sneader, W. Drug discovery a history; John Wiley & Sons, 2005, pp. 250-268.
[http://dx.doi.org/10.1002/0470015535]
[46]
Fischer, J.; Ganellin, C.R. Analogue-based Drug Discovery; John Wiley & Sons, 2006, pp. 505-521.
[http://dx.doi.org/10.1002/3527608001]
[47]
VIDEX (didanosine): chewable/dispersible buffered tablets; buffered powder for oral solution; pediatric powder for oral solution. Product information, 2000 July;.
[48]
Georgiev, V.S. National institute of allergy and infectious diseases. NIH, 2009, 2, 417-426.
[49]
Fauci, A.S. HIV and AIDS: 20 years of science. Nat. Med., 2003, 9(7), 839-843.
[http://dx.doi.org/10.1038/nm0703-839] [PMID: 12835701]
[50]
HIVID (zalcitabine) tablets. Product information, 2002 September;.
[51]
Ogden, R.C.; Skowron, G. Reverse transcriptase inhibitors in HIV/AIDS therapy; Humana press, 2006, pp. 33-63.
[52]
LaFemina, R.L. Antiviral research strategies in antiviral drug discovery; AMS press, 2009, pp. 51-70.
[http://dx.doi.org/10.1128/9781555815493]
[53]
Diederich, W.E.; Steuber, H. Therapy of Viral Infections.Topics in Medicinal Chemistry; Springer, 2015, pp. 6-10.
[54]
Lamivudine. The American Society of Health-System Pharmacists. Archived from the original on 2 June, . 2016.
[55]
World Health Organization model list of essential medicines: 21st list; World Health Organization: Geneva, 2019.
[56]
Otto, M.J. New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. Curr. Opin. Pharmacol., 2003, 9(7), 839-843.
[PMID: 15351346]
[57]
Brunton, L.; Lazo, J.; Parker, K. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th ed; McGraw-Hill, 2006, pp. 1280-1292.
[58]
FDA Approved Drug Products: Emtriva (Emtricitabine) Oral Capsules.,. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021896s026lbl.pdf [Accessed February 06, 2020];
[59]
Orkin, C.; Llibre, J.M.; Gallien, S.; Antinori, A.; Behrens, G.; Carr, A. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence. HIV Med., 2018, 19(1), 18-32.
[http://dx.doi.org/10.1111/hiv.12534] [PMID: 28737291]
[60]
Entecavir. The American Society of Health-System Pharmacists. Archived from the original on 20 December, 2016.
[61]
Matthews, S.J. Entecavir for the treatment of chronic hepatitis B virus infection. Clin. Ther., 2006, 28(2), 184-203.
[http://dx.doi.org/10.1016/j.clinthera.2006.02.012] [PMID: 16678641]
[62]
Sims, K.A.; Woodland, A.M. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection. Pharmacotherapy, 2006, 26(12), 1745-1757.
[http://dx.doi.org/10.1592/phco.26.12.1745] [PMID: 17125436]
[63]
Yamanaka, G.; Wilson, T.; Innaimo, S.; Bisacchi, G.S.; Egli, P.; Rinehart, J.K.; Zahler, R.; Colonno, R.J. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother., 1999, 43(1), 190-193.
[http://dx.doi.org/10.1128/AAC.43.1.190] [PMID: 9869593]
[64]
ZIAGEN(R) oral tablets, oral solution, abacavir sulfate oral tablets, oral solution. In: ViiV Healthcare (per Manufacturer), Research Triangle Park, NC; , 2015.
[65]
Marcellin, P.; Chang, T.T.; Lim, S.G.; Tong, M.J.; Sievert, W.; Shiffman, M.L.; Jeffers, L.; Goodman, Z.; Wulfsohn, M.S.; Xiong, S.; Fry, J.; Brosgart, C.L. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med., 2003, 348(9), 808-816.
[http://dx.doi.org/10.1056/NEJMoa020681] [PMID: 12606735]
[66]
Manolakopoulos, S.; Bethanis, S.; Koutsounas, S.; Goulis, J.; Vlachogiannakos, J.; Christias, E.; Saveriadis, A.; Pavlidis, C.; Triantos, C.; Christidou, A.; Papatheodoridis, G.; Karamanolis, D.; Tzourmakliotis, D. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment. Pharmacol. Ther., 2008, 27(3), 266-273.
[http://dx.doi.org/10.1111/j.1365-2036.2007.03567.x] [PMID: 17988233]
[67]
Fisher, E.J.; Chaloner, K.; Cohn, D.L.; Grant, L.B.; Alston, B.; Brosgart, C.L.; Schmetter, B.; El-Sadr, W.M.; Sampson, J. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS, 2001, 15(13), 1695-1700.
[http://dx.doi.org/10.1097/00002030-200109070-00013] [PMID: 11546945]
[68]
A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Med., 2002, 3(4), 229-238.
[http://dx.doi.org/10.1046/j.1468-1293.2002.00111.x] [PMID: 12444940]
[69]
Oliyai, R.; Fardis, M. 8.06–Hepsera. Case Histories: In: Comprehensive Medicinal Chemistry II; , 2007; 8, pp. 59-63.
[70]
Uslu, B.; Ozkan, S.A. Anodic voltammetry of abacavir and its determination in pharmaceuticals and biological fluids. Electrochim. Acta, 2004, 49(25), 4321-4329.
[http://dx.doi.org/10.1016/j.electacta.2004.03.041]
[71]
Cheraghi, S.; Taher, M.A.; Karimi-Maleh, H. A sensitive amplified sensor based on improved carbon paste electrode with 1-methyl-3-octylimidazolium tetrafluoroborate and ZnO/CNTs nanocomposite for differential pulse voltammetric analysis of raloxifene. Appl. Surf. Sci., 2017, 420, 882-885.
[http://dx.doi.org/10.1016/j.apsusc.2017.05.218]
[72]
Aarsland, D.; Larsen, J.P.; Lim, N.G.; Janvin, C.; Karlsen, K.; Tandberg, E.; Cummings, J.L. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 1999, 67(4), 492-496.
[http://dx.doi.org/10.1136/jnnp.67.4.492] [PMID: 10486397]
[73]
Cummings, J.L. Depression and Parkinson’s disease: a review. Am. J. Psychiatry, 1992, 149(4), 443-454.
[http://dx.doi.org/10.1176/ajp.149.4.443] [PMID: 1372794]
[74]
Allain, H.; Schuck, S.; Mauduit, N. Depression in Parkinson’s disease. BMJ, 2000, 320(7245), 1287-1288.
[http://dx.doi.org/10.1136/bmj.320.7245.1287] [PMID: 10807601]
[75]
Van Camp, G.; Flamez, A.; Cosyns, B.; Weytjens, C.; Muyldermans, L.; Van Zandijcke, M.; De Sutter, J.; Santens, P.; Decoodt, P.; Moerman, C.; Schoors, D. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet, 2004, 363(9416), 1179-1183.
[http://dx.doi.org/10.1016/S0140-6736(04)15945-X] [PMID: 15081648]
[76]
Karimi-Maleh, H.; Amini, F.; Akbari, A.; Shojaei, M. Amplified electrochemical sensor employing CuO/SWCNTs and 1-butyl-3-methylimidazolium hexafluorophosphate for selective analysis of sulfisoxazole in the presence of folic acid. J. Colloid Interface Sci., 2017, 495, 61-67.
[http://dx.doi.org/10.1016/j.jcis.2017.01.119] [PMID: 28189110]
[77]
Jain, A.K.; Gupta, V.K.; Singh, L.P.; Raisoni, J.R. A comparative study of Pb2+ sensors based on derivatized tetrapyrazole and calix[4]arene receptors. Electrochim. Acta, 2006, 51(12), 2547-2553.
[http://dx.doi.org/10.1016/j.electacta.2005.07.040]
[78]
Ozkan, S. Electroanalytical Methods in Pharmaceutical Analysis and Their Validation, 1st ed; HNB Publishing: New York, 2012.
[79]
Bozal, B.; Uslu, B.; Ozkan, S.A. A review of electroanalytical techniques for determination of anti-hiv drugs. International Journal of Electrochemistry. Article ID, 2011, 343947, 1-17.
[80]
Fernández Torres, R.; Callejón Mochón, M.; Jiménez Sánchez, J.C.; Bello López, M.A.; Guiraúm Perez, A. Electrochemical behaviour and determination of acrivastine in pharmaceuticals and human urine. J. Pharm. Biomed. Anal., 2002, 30(4), 1215-1222.
[http://dx.doi.org/10.1016/S0731-7085(02)00463-6] [PMID: 12408912]
[81]
Abdine, H.; Belal, F. Polarographic behaviour and determination of acrivastine in capsules and human urine. Talanta, 2002, 56(1), 97-104.
[http://dx.doi.org/10.1016/S0039-9140(01)00539-2] [PMID: 18968484]
[82]
Santos, A.L.; Takeuchi, R.M.; Mariotti, M.P.; De Oliveira, M.F.; Zanoni, M.V.B.; Stradiotto, N.R. Study of electrochemical oxidation and determination of albendazole using a glassy carbon-rotating disk electrode. Farmaco, 2005, 60(8), 671-674.
[http://dx.doi.org/10.1016/j.farmac.2005.05.004] [PMID: 15961086]
[83]
Wang, J. Analytical Electrochemistry, 2nd ed; Wiley-VCH: New York, 2006.
[http://dx.doi.org/10.1002/0471790303]
[84]
Smyth, M.R.; Vos, J.G. Analytical Voltammetry, 1st ed; Elsevier Science Pub: Amsterdam, 1992, Vol. 27, .
[85]
Wang, J. Electroanalytical Techniques in Clinical Chemistry and Laboratory Medicine, 1st ed; VCH: New York, 1988.
[86]
Bard, A.J.; Faulkner, L.R. Electrochemical Methods, Fundamentals and Applications, 2nd ed; Wiley: New York, 2001.
[87]
Zoski, C.G. Handbook of Electrochemistry, 1st ed; Elsevier Pub: Amsterdam, 2007.
[88]
Gupta, V.K.; Jain, R.; Radhapyari, K.; Jadon, N.; Agarwal, S. Voltammetric techniques for the assay of pharmaceuticals--a review. Anal. Biochem., 2011, 408(2), 179-196.
[http://dx.doi.org/10.1016/j.ab.2010.09.027] [PMID: 20869940]
[89]
Harvey, D. Modern Analytical Chemistry, 1st ed; McGraw-Hill Companies: United States of America, 2000.
[90]
Ozkan, S.A. Principles and techniques of electroanalytical stripping methods for pharmaceutically active compounds in forms and biological samples. Curr. Pharm. Anal., 2009, 5(2), 127-143.
[http://dx.doi.org/10.2174/157341209788172870]
[91]
Wang, J. Analytical Electrochemistry, 2nd ed; Wiley-VCH: New York, 2000.
[http://dx.doi.org/10.1002/0471228230]
[92]
Hart, J.P. Electroanalysis of Biologically Important Compounds, 1st ed; Ellis Harwood Ltd.: Chichester, UK, 1990.
[93]
Kellner, R.; Mermet, J.M.; Otto, M.; Valcárcel, M.; Widmer, H.M. Analytical Chemistry: A Modern Approach to Analytical Science, 2nd ed; Wiley-VCH: Weinheim, 2004.
[94]
Gosser, D.K. Jr Cyclic Voltammetry: Simulation and Analysis of Reaction Mechanisms, 1st ed; Wiley-VCH: New York, 1993.
[95]
Christian, G. Analytical Chemistry, 6th ed; Wiley: Hoboken, NJ, 2004.
[96]
Uslu, B.; Ozkan, S.A. Solid electrodes in electroanalytical chemistry: present applications and prospects for high throughput screening of drug compounds. Comb. Chem. High Throughput Screen., 2007, 10(7), 495-513.
[http://dx.doi.org/10.2174/138620707782152425] [PMID: 17979634]
[97]
Scholz, F. Electroanalytical Methods, 2nd ed; Springer-Verlag: Berlin, Heidelberg, 2010.
[http://dx.doi.org/10.1007/978-3-642-02915-8]
[98]
Uslu, B.; Ozkan, S.A. Electroanalytical methods for the determination of pharmaceuticals: A review of recent trends and developments. Anal. Lett., 2011, 44(16), 2644-2702.
[http://dx.doi.org/10.1080/00032719.2011.553010]
[99]
Uslu, B.; Ozkan, S.A. Electroanalytical application of carbon based electrodes to the pharmaceuticals. Anal. Lett., 2007, 40(5), 817-853.
[http://dx.doi.org/10.1080/00032710701242121]
[100]
Ağın, F.; Serdaroğlu, V. Voltammetric determination of nimesulide using multiwalled carbon nanotubes modified carbon paste electrode. Turk. J. Pharm. Sci., 2016, 13(3), 335-341.
[101]
Mirceski, V.; Komorsky-Lovric, S.; Lovric, M. Square Wave Voltammetry, 1st ed; Springer-Verlag: Berlin, Heidelberg, 2007.
[http://dx.doi.org/10.1007/978-3-540-73740-7]
[102]
Ağın, F. Electrochemical determination of amoxicillin on a poly(acridine orange) modified glassy carbon electrode. Anal. Lett., 2016, 49(9), 1366-1378.
[http://dx.doi.org/10.1080/00032719.2015.1101602]
[103]
Leandro, K.C.; Moreira, J.C.; Farias, P.A.M. Determination of zidovudine in pharmaceuticals by differential pulse voltammetry. Anal. Lett., 2010, 43(12), 1951-1957.
[http://dx.doi.org/10.1080/00032711003687021]
[104]
Pecková, K.; Navrátil, T.; Yosypchuk, B.; Moreira, J.C.; Leandro, K.C.; Barek, J. Voltammetric determination of azidothymidine using silver solid amalgam electrodes. Electroanalysis, 2009, 21(15), 1750-1757.
[http://dx.doi.org/10.1002/elan.200904660]
[105]
Trnková, L.; Kizek, R.; Vacek, J. Square wave and elimination voltammetric analysis of azidothymidine in the presence of oligonucleotides and chromosomal DNA. Bioelectrochemistry, 2004, 63(1-2), 31-36.
[http://dx.doi.org/10.1016/j.bioelechem.2003.10.012] [PMID: 15110244]
[106]
Vacek, J.; Zdeneoek Andrysík, Z.; Trnková, L.; Kizek, R. Determination of azidothymidine ¬- an antiproliferative and virostatic drug by square-wave voltammetry. Electroanalysis, 2004, 16(3), 224-230.
[http://dx.doi.org/10.1002/elan.200302787]
[107]
Karimi-Maleh, K.; Asma Bananezhad, A.; Ganjali, M.R.; Norouzi, P.; Sadrnia, A. Surface amplification of pencil graphite electrode with polypyrrole and reduced graphene oxide for fabrication of a guanine/adenine DNA based electrochemical biosensors for determination of didanosine anticancer drug. Appl. Surf. Sci., 2018, 441, 55-60.
[http://dx.doi.org/10.1016/j.apsusc.2018.01.237]
[108]
Leandro, K.C.; Moreira, J.C.; Farias, P.A.M. Determination of zalcitabine in medicaments by differential pulse voltammetry. Journal of Pharmaceutics. Article ID, 2013, 495814, 1-6.
[109]
Dogan, B.; Uslu, B.; Suzen, S.; Ozkan, S.A. Electrochemical evaluation of nucleoside analogue lamivudine in pharmaceutical dosage forms and human serum. Electroanalysis, 2005, 17(20), 1886-1894.
[http://dx.doi.org/10.1002/elan.200503307]
[110]
Jain, R.; Jadon, N.; Radhapyari, K. Cathodic adsorptive stripping voltammetric studies on lamivudine: an antiretroviral drug. J. Colloid Interface Sci., 2007, 313(1), 254-260.
[http://dx.doi.org/10.1016/j.jcis.2007.04.003] [PMID: 17499263]
[111]
Leandro, K.C.; Moreira, J.C.; Farias, P.A.M. Differential pulse voltammetric studies on lamivudine: an antiretroviral drug. Am. J. Anal. Chem., 2013, 4, 47-51.
[http://dx.doi.org/10.4236/ajac.2013.46A007]
[112]
Mulik, B.B.; Dhumal, S.T.; Rajkumar, R. Harale, R.R.; Kiran R. Kharat, K.R.; Sathe, B.R. Electrochemical studies of anti-HIV drug emtricitabine: oxidative determination and improved antimicrobial activity. ChemElectroChem, 2018, 5, 3926-3931.
[http://dx.doi.org/10.1002/celc.201801228]
[113]
Jhankal, K.K.; Sharma, A.; Sharma, R.; Sharma, D.K. Quantification of antiviral drug entecavir in pharmaceutical formulation by voltammetric techniques. J. Pharm. Sci. & Res., 2015, 7(1), 10-13.
[114]
Tandel, R.D.; Naik, R.S.; Seetharamappa, J. Electrochemical characteristics and electrosensing of an antiviral drug, entecavir via synergic effect of graphene oxide nanoribbons and ceria nanorods. Electroanalysis, 2017, 29, 1301-1309.
[http://dx.doi.org/10.1002/elan.201600492]
[115]
Uslu, B.; Özkan, S.A. Anodic voltammetry of abacavir and its determination in pharmaceuticals and biological fluids. Electrochim. Acta, 2004, 49, 4321-4329.
[http://dx.doi.org/10.1016/j.electacta.2004.03.041]
[116]
Dogan, B.; Uslu, B.; Ozkan, S.A.; Zuman, P. Electrochemical determination of HIV drug Abacavir based on its reduction. Anal. Chem., 2008, 80(1), 209-216.
[http://dx.doi.org/10.1021/ac0713151] [PMID: 18041821]
[117]
Ashrafi, A.M.; Kurbanoglu, S.; Vytŕas, K.; Uslu, B.; Ozkan, S.A. Electrochemical mechanism and sensitive assay of antiretroviral drug Abacavir in biological sample using multiwalled carbon nanotube modified pyrolytic graphite electrode. J. Electroanal. Chem. , 2014, 712, 178-184.
[http://dx.doi.org/10.1016/j.jelechem.2013.11.012]
[118]
Dorraji, P.S.; Noori, M.; Fotouhi, L. Voltammetric determination of adefovir dipivoxil by using a nanocomposite prepared from molecularly imprinted poly(o-phenylenediamine), multi-walled carbon nanotubes and carbon nitride. Mikrochim. Acta, 2019, 186(7), 427.
[http://dx.doi.org/10.1007/s00604-019-3538-y] [PMID: 31187299]

Rights & Permissions Print Cite
Article Metrics
9
1
© 2024 Bentham Science Publishers | Privacy Policy